Materias dentro de su búsqueda.
Mostrando 61 - 80 Resultados de 1,014 Para Buscar '"Shareholder"', tiempo de consulta: 0.26s Limitar resultados
  1. 61
    “…(Employee, Shareholder)Merck & Co., Inc. (Employee, Shareholder) C. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1460. Imipenem/Cilastatin (IMI)/Relebactam (REL) in Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia (HABP/VABP): Subgroup Analyses of Critically Ill Patients in the RESTORE-IMI 2 Trial
  2. 62
    “…DISCLOSURES: Parul Patel, PharmD, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Susan L. Ford, PharmD, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Mark Baker, PhD, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Claudia Meyer, MBChB, MRCP, MSc, FRCPath, DTM&H, GlaxoSmithKline (Employee, Shareholder) Louise Garside, PhD, GlaxoSmithKline (Employee) Ronald D’Amico, DO, MSc, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Rodica Van Solingen-Ristea, MD, Janssen Research and Development (Employee)ViiV Healthcare (Employee) Herta Crauwels, PhD, Janssen (Employee) Joseph Polli, PhD, FAAPS, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Ciara Seal, BS, GlaxoSmithKline (Employee, Shareholder) Shanker Thiagarajah, MB ChB, GlaxoSmithKline (Employee, Shareholder) Eileen Birmingham, MD, MPH, Janssen Research and Development (Employee, Shareholder) William Spreen, PharmD, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Bryan Baugh, MD, Janssen, Johnson & Johnson (Employee, Shareholder) Matthew Bosse, DO, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Vani Vannappagari, MBBS, MPH, PhD, ViiV Healthcare Limited (Employee)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    885. Pregnancy Outcomes and Pharmacokinetics in Pregnant Women Living with HIV Exposed to Long-Acting Cabotegravir and Rilpivirine in Clinical Trials
  3. 63
    “…Aline Barth, MSC;PHD, GlaxoSmithKline plc. (Employee, Shareholder, Employee of and shareholder in GlaxoSmithKline plc.) …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1115. Evaluation of Gepotidacin (GSK2140944) Pharmacokinetics and Food Effect in Japanese Subjects
  4. 64
    “…(Employee, Shareholder)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    511. Treatment with Molnupiravir in the MOVe-In and MOVe-Out Clinical Trials Results in an Increase in Transition Mutations Across the SARS-CoV-2 Genome
  5. 65
    “…Jansen, PhD, Pfizer (Employee, Shareholder) William C. Gruber, MD, Pfizer (Employee, Shareholder) Daniel Scott, MD, Pfizer (Employee, Shareholder) Wendy Watson, MD, Pfizer (Employee, Shareholder)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    3. Phase 3 Pivotal Evaluation of 20-valent Pneumococcal Conjugate Vaccine (PCV20) Safety, Tolerability, and Immunologic Noninferiority in Participants 18 Years and Older
  6. 66
    “…Henn, Seres Therapeutics: Employee and Shareholder, Salary and Stock Options; C. Ford, Seres Therapeutics: Employee and Shareholder, Salary and Stock Options; E. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Gastrointestinal Tract Microbiome Dynamics Following Treatment with SER-109, an Investigational Oral Microbiome Therapeutic to Reduce the Recurrence of Clostridium difficile Infection (CDI)
  7. 67
    “…(Employee, Shareholder)Merck & Co., Inc. (Employee, Shareholder)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1230. Clinical and Microbiologic Outcomes by Causative Pathogen in Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Treated with Imipenem/Cilastatin (IMI)/Relebactam (REL) Versus Piperacillin/Tazobactam (PIP/TAZ)
  8. 68
    “…(Employee, Shareholder)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    636. A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Quadrivalent Dengue Vaccine (V181)
  9. 69
    “…Biochemistry, ChromaCode (Employee, Shareholder)ChromaCode (Employee, Shareholder)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    369. Alternative Workflow for SARS-CoV-2 Testing Using a Heat Lysis Protocol for Respiratory Specimens
  10. 70
    “…(Shareholder)Novavax, Inc. (Shareholder)Sarepta Therapeutics (Shareholder)Thermo Fisher Scientific (Shareholder) Princy N. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    286. Infectious Complications and Antimicrobial Utilization in Hospitalized Patients with COVID-19
  11. 71
    “…(Employee, Shareholder) S. Y. Amy Cheung, PhD, Certara (Employee, Shareholder) Rik de Greef, MSc, Certara (Employee, Shareholder) Jeffrey R. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1010. Cross-Species Translation of Correlates of Protection for COVID-19 Vaccine Candidates Using Quantitative Tools
  12. 72
    “…Perron, Lumed Inc., the company that commercializes APSS: Shareholder, Shareholder; V. Nault, Lumed Inc., the company that commercializes APSS: Shareholder, Shareholder; M. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    An Offer You Can’t Refuse: Clinical Impact of Accepting or Rejecting a Recommendation from an Antibiotic Stewardship Program
  13. 73
    “…(Employee, Shareholder) Marcela Gonzalez, MD, MSD (Employee, Shareholder) Irina Alekseeva, MD, PhD, MSD (Employee, Shareholder) Diego Lopez, MD, MSD (Employee, Shareholder) Brune Akrich, MD, MSD (Employee, Shareholder) Daniel F. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1603. Comparison of Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Meropenem/Vaborbactam Activity Against P. aeruginosa: A Multicenter Evaluation
  14. 74
    “…(Employee, Shareholder)Merck & Co., Inc. (Employee, Shareholder)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1574. Multivariate Regression Analysis to Determine Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Trial
  15. 75
    “…Caro, Merck: Employee and Shareholder, Salary and stock options. B. Maas, Merck: Employee and Shareholder, Salary and stock options. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1971. A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of a Respiratory Syncytial Virus (RSV) Neutralizing Monoclonal Antibody (MK-1654) in Healthy Subjects
  16. 76
    “…(Employee, Shareholder) Miriam Huntley, PhD, Day Zero Diagnostics (Employee, Shareholder)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    152. rapid Ultra-high Enrichment of Bacterial Pathogens at Low Concentration from Blood for Species ID and AMR Prediction Using Nanopore Sequencing
  17. 77
    “…Perry, PhD, GSK: Employee and shareholder Salim Janmohamed, MD, GSK: Employee and shareholder Amanda Sheets, PhD, GSK: Employee and shareholder Jeremy Dennison, MD, GSK: Employee and shareholder Helen Millns, PhD, GSK: Employee and shareholder Emily Jarvis, MSc, GSK: Employee and shareholder Nicole E. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2832. Gepotidacin Efficacy in E. coli Drug-Resistant Phenotypes: A Pooled Analysis of the EAGLE-2 and EAGLE-3 Randomized Controlled Trials in Uncomplicated Urinary Tract Infection
  18. 78
    “…DISCLOSURES: Ronald D'Amico, DO, MSc, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Paul Benn, MB ChB FRCP, ViiV Healthcare (Employee, Shareholder) Cynthia C. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials
  19. 79
    “…(Employee, Shareholder) Les Tari, PhD, Cidara Therapeutics (Shareholder)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1276. Evaluation of CD377, a Novel Antiviral Fc-Conjugate (AVC), In Vitro Activity and In Vivo Efficacy in Immune-Competent and -Deficient (SCID) Lethal Mouse Models
  20. 80
    “…Jansen, PhD, Pfizer (Employee, Shareholder) William C. Gruber, MD, Pfizer (Employee, Shareholder) Wendy Watson, MD, Pfizer (Employee, Shareholder)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1240. Persistence of Circulating Antibody Through 12 Months Following Vaccination With a 20-Valent Pneumococcal Conjugate Vaccine in Adults 60–64 Years of Age
Herramientas de búsqueda: RSS